The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.689
https://www.valueinhealthjournal.com/article/S1098-3015(14)02619-9/fulltext
Title :
The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02619-9&doi=10.1016/j.jval.2014.08.689
First page :
A343
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
114